Clinical Trial Update: Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes [Phase 1]

View source ↗

Summary

Phase 1 randomized, double-blind, placebo-controlled, four-way crossover study assessing safety, tolerability, and pharmacokinetics of CM3.1-AC100 in adults wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• CM3.1-AC100 (CM3.1-AC100)

Snippet

Sponsor: CellMed AG, a subsidiary of BTG plc. | Conditions: Type II Diabetes Mellitus | Phase 1 | Status: COMPLETED